ViroMissile IDOV-Safe Phase 1 Data to Be Presented at the 2026 ASCO Annual Meeting Press Releases ViroMissile IDOV-Safe Phase 1 Data to Be Presented at the 2026 ASCO Annual Meeting
ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance Press Releases ViroMissile Expands Phase I IDOV-ImmuneTM Trial to U.S. Sites Following IND Clearance
ViroMissile Appoints Michael G. Wood as Chief Business Officer Press Releases ViroMissile Appoints Michael G. Wood as Chief Business Officer
ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors Press Releases ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors
ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer Press Releases ViroMissile Appoints Mark Bertagnolli as Chief Operating Officer
ViroMissile honored by Life Sciences Review Press Releases ViroMissile honored by Life Sciences Review
